Table 1. Sample characteristics, N = 397.
| N | % | |
|---|---|---|
| Age group (years) | ||
| <40 | 59 | 14.9 |
| 40–49 | 138 | 34.8 |
| 50–59 | 146 | 36.8 |
| ≥60 | 54 | 13.6 |
| Number of comorbid conditions | ||
| None | 293 | 73.8 |
| 1 | 67 | 16.9 |
| 2 or more | 37 | 9.3 |
| Stage | ||
| I | 77 | 19.4 |
| II | 223 | 56.2 |
| III | 97 | 24.4 |
| Body mass index | ||
| Healthy weight (≥18.5 to <25) | 80 | 20.2 |
| Overweight (≥25 to <30) | 137 | 34.5 |
| Obese (≥30 to <35) | 95 | 23.9 |
| Severely obese (≥35) | 85 | 21.4 |
| Race/Ethnicity | ||
| Non-Hispanic white | 122 | 30.7 |
| Non-Hispanic black | 21 | 5.3 |
| Hispanic | 226 | 56.9 |
| Asian/Pacific islander | 28 | 7.1 |
| Years of education | ||
| Less than high school | 182 | 45.8 |
| High school graduate | 215 | 54.2 |
| Social support | ||
| Low | 95 | 23.9 |
| High | 302 | 76.1 |
| Site of treatment | ||
| Academic | 289 | 72.8 |
| Non-academic | 108 | 27.2 |
| Hormone receptor status | ||
| ER and/or PR positive | 260 | 65.5 |
| ER and PR negative | 137 | 34.5 |
|
| ||
| Mean | SD | |
|
| ||
| PEPPI (range 0–50) | 37.4 | 12.0 |
ER estrogen receptor, PR progesterone receptor, PEPPI patient efficacy in patient–provider interactions, SD standard deviation